<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Excluding <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, a total of 92 consecutive patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> showing less than 20% blasts in the bone marrow were analyzed </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated the clinical significance of the WHO and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> 2000 classifications by reviewing each <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patient according to the classification </plain></SENT>
<SENT sid="2" pm="."><plain>The WHO criteria classified the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients into 36 with RA, 22 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e> and 33 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, whereas according to the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> 2000 criteria there were 19 RAEB-I patients and 15 RAEB-II patients </plain></SENT>
<SENT sid="3" pm="."><plain>Based on the WHO classification, the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e> patients had higher platelet counts and percentages of blasts among BM cells than the RA patients (P = 0.0018, P = 0.0001) </plain></SENT>
<SENT sid="4" pm="."><plain>Twenty percent of the RA patients, 44.8% of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e> patients, and 70.8% of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> patients had cytogenetic abnormalities </plain></SENT>
<SENT sid="5" pm="."><plain>Among them, the poor karyotype was present in 6.7% of the RA patients, 21.0% of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e> patients and 41.6% of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> patients </plain></SENT>
<SENT sid="6" pm="."><plain>The rate of <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> <z:hpo ids='HP_0011420'>death</z:hpo> was 14.3% in the RA patients, 67.7% in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> patients and 50.0% in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e> patients </plain></SENT>
<SENT sid="7" pm="."><plain>Analysis of survival times revealed significant differences between RA and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e> patients (P = 0.0482) </plain></SENT>
<SENT sid="8" pm="."><plain>The clinical features of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e> patients were intermediate between those of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and RA patients </plain></SENT>
<SENT sid="9" pm="."><plain>There was no difference between the clinical features of the <z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB-I</z:e> and <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB-II</z:e> patients in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> 2000 classification </plain></SENT>
</text></document>